Batten Disease (NCL) Detection: Genetic, Enzyme, Imaging & Biopsy Methods

Neuronal Ceroid Lipofuscinoses (NCLs, Batten disease) are 14+ autosomal recessive lysosomal storage disorders (CLN1–14). Diagnosis requires a tiered approach.

Diagnostic Algorithm

  1. Clinical suspicion: Regression, seizures, vision loss, ataxia, dementia (childhood onset).
  2. Genetic testing (first-line):
    • Targeted NCL panel (CLN1–14) or exome/genome sequencing.
    • Identifies pathogenic variants; confirms diagnosis, enables carrier testing.
  3. Enzyme assay (if gene unknown/VUS):
    • PPT1 (CLN1), TPP1 (CLN2), CLN3, CLN5, CLN8 – measured in leukocytes/fibroblasts.
    • Deficient activity confirms specific type.
  4. MRI brain:
    • Cerebral/cerebellar atrophy.
    • Thalamus hyperintensity (CLN3).
    • Posterior white matter changes.
  5. EEG: Background slowing, epileptiform discharges, photoparoxysmal response.
  6. Ophthalmology: ERG (electroretinogram) – early rod/cone loss; macular bull's-eye.
  7. Biopsy (rare now): Skin/rectal/conjunctival – fingerprint/curvilinear/granular osmiophilic deposits (EM).

Multidisciplinary Care

  • Neurology, genetics, ophthalmology, metabolism, palliative care.
  • Clinical trials: enzyme replacement (CLN2 cerliponase alfa), gene therapy, small molecules.

Early genetic diagnosis enables family counseling and trial access.

Gum Disease - Related Articles